"Following the inspection by the United States Food and Drug Administration (USFDA) at the Patalganga manufacturing facility of the company from November 4, 2019 to November 13, 2019, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection," the homegrown pharma major said in a filing to the BSE.Cipla announces closure of USFDA inspection at Patalganga facility
"Following the inspection by the United States Food and Drug Administration (USFDA) at the Patalganga manufacturing facility of the company from November 4, 2019 to November 13, 2019, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection," the homegrown pharma major said in a filing to the BSE.
Subscribe to:
Post Comments (Atom)
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
"Paytm is now empowering feature phone users to recharge for their Vodafone Idea numbers with just a valid UPI ID. Along with the tele...
No comments:
Post a Comment